Linezolid Population Pharmacokinetic Model in Plasma and Cerebrospinal Fluid Among Patients With Tuberculosis Meningitis
Year: 2023
Type: article
Abstract: BACKGROUND: Linezolid is evaluated in novel treatment regimens for tuberculous meningitis (TBM). Linezolid pharmacokinetics have not been characterized in this population, particularly in cerebrospinal fluid (CSF), as well as, following its co-administration with high-dose rifampicin. We aimed to characterize linezolid plasma and CSF pharmacokinetics in adults with TBM. METHODS: In the LASER-TBM pharmacokinetic substudy, the intervention groups received high-dose rifampicin (35 mg/kg) plus 1200 mg/day of linezolid for 28 days, which was then reduced to 600 mg/day. Plasma sampling was done on day 3 (intensive) and day 28 (sparse). A lumbar CSF sample was obtained on both visits. RESULTS: Thirty participants contributed 247 plasma and 28 CSF observations. Their median age and weight were 40 years (range, 27-56) and 58 kg (range, 30-96). Plasma pharmacokinetics was described by a 1-compartment model with first-order absorption and saturable elimination. Maximal clearance was 7.25 L/h, and the Michaelis-Menten constant was 27.2 mg/L. Rifampicin cotreatment duration did not affect linezolid pharmacokinetics. CSF-plasma partitioning correlated with CSF total protein up to 1.2 g/L, where the partition coefficient reached a maximal value of 37%. The plasma-CSF equilibration half-life was ∼3.5 hours. CONCLUSIONS: Linezolid was readily detected in CSF despite high-dose rifampicin coadministration. These findings support continued clinical evaluation of linezolid plus high-dose rifampicin for the treatment of TBM in adults. Clinical Trials Registration. ClinicalTrials.gov (NCT03927313).
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,536
Funders: Wellcome Trust, Francis Crick Institute, UK Research and Innovation, ACT Government, International Maternal Pediatric Adolescent AIDS Clinical Trials Network, Cancer Research UK, University of Cape Town, National Institutes of Health, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases, Fogarty International Center, National Institute of Child Health and Human Development, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Organization for Women
Awards: G1571747198, G1819583291, Translational approaches to improve understanding and outcome in Tuberculous meningitis, G2540682662, G3135292464, G336435875, G3810609436, Centre for Infectious Diseases Research in Africa (CIDRI-Africa), G4758841269, G54722676, Centre for Infectious Diseases Research in Africa (CIDRI-Africa), International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group, Characterizing the pharmacokinetics of high dose rifampicin and linezolid in a randomized controlled trial for HIV-associated tuberculous meningitis, G622809771, G7647985552, G7692990666, G7742187551, G8953291578, G9000014638, G9000039438, G9000292181, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, HIV-associated Tuberculosis Training Program (HATTP), AIDS Clinical Trial Group Laboratory Center, Statistical and Data Management Center (SDMC), Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG), PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis, IMPAACT Leadership Group
OpenAlex ID: W4386979679
